onr:"swepub:oai:DiVA.org:uu-264326"
Search: onr:"swepub:oai:DiVA.org:uu-264326" > Primary graft failu...
- 1 of 1
- Previous record
- Next record
- To hitlist
Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies
-
- Olsson, R. F. (author)
- Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, S-14186 Stockholm, Sweden.
-
- Logan, B. R. (author)
- Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
-
- Chaudhury, S. (author)
- Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplant, Chicago, IL USA.
- show more...
- show less...
- (creator_code:org_t)
- 2015-03-16
- 2015
- English.
- In: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 29:8, s. 1754-1762
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Clinical outcomes after primary graft failure (PGF) remain poor. Here we present a large retrospective analysis (n = 23 272) which investigates means to prevent PGF and early detection of patients at high risk. In patients with hematologic malignancies, who underwent their first myeloablative allogeneic hematopoietic cell transplantation, PGF was reported in 1278 (5.5%), and there was a marked difference in PGFs using peripheral blood stem cell compared with bone marrow grafts (2.5 vs 7.3%; P<0.001). A fourfold increase of PGF was observed in myeloproliferative disorders compared with acute leukemia (P<0.001). Other risk factors for PGF included recipient age <30, HLA mismatch, male recipients of female donor grafts, ABO incompatibility, busulfan/cyclophosphamide conditioning and cryopreservation. In bone marrow transplants, total nucleated cell doses <= 2.4 x 10(8) per kg were associated with PGF (odds ratio 1.39; P<0.001). The use of tacrolimus-based immunosuppression and granulocyte colony-stimulating factor were associated with decreased PGF risk. These data, allow clinicians to do more informed choices with respect to graft source, donor selection, conditioning and immunosuppressive regimens to reduce the risk of PGF. Moreover, a novel risk score determined on day 21 post transplant may provide the rationale for an early request for additional hematopoietic stem cells.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Olsson, R. F.
- Logan, B. R.
- Chaudhury, S.
- Zhu, X.
- Akpek, G.
- Bolwell, B. J.
- show more...
- Bredeson, C. N.
- Dvorak, C. C.
- Gupta, V.
- Ho, V. T.
- Lazarus, H. M.
- Marks, D. I.
- Ringden, O. T. H ...
- Pasquini, M. C.
- Schriber, J. R.
- Cooke, K. R.
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Leukemia
- By the university
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
